相关实验视频
Updated: Apr 20, 2026

14:57
Yeast As a Chassis for Developing Functional Assays to Study Human P53
Published on: August 4, 2019
10.2K
通过双重MdmX/Mdm2抑制剂在癌细胞中有效地重新激活p53
Lingyun Qin1, Fei Yang, Cindy Zhou
1Department of Biotechnology and Collaborative Innovation Center for Industrial Fermentation, Hubei University of Technology , Wuhan 430068, China.
Journal of the American Chemical Society
|December 3, 2014
概括
一种新的双小分子药物有效地通过向癌细胞中的Mdm2/MdmX来重新激活p53通路. 这种方法为过度表达这些蛋白质的癌症提供了一个有希望的治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- 异常的p53-Mdm2/MdmX相互作用在约50%的人类癌症中损害p53功能.
- 过度表达Mdm2和/或MdmX是癌症中p53无活化的常见机制.
- 抑制Mdm2和MdmX都在促进癌细胞亡方面表现出比单一向抑制更大的有效性.
研究的目的:
- 开发和验证一种针对Mdm2和MdmX的双重小分子抗剂.
- 评估这种双抗体在癌症模型中重新激活p53通路的疗效.
- 为了确定Mdm2/MdmX过度表达的癌症的潜在治疗候选者.
主要方法:
- 基于MdmX.的细分突变分析的合理药物设计.
- 使用Mdm2 N-终端域的晶体结构与nutlin-3a复合.
- 在过度表达MdmX和/或Mdm2.2的癌细胞模型中测试双抗体.
主要成果:
- 双重小分子抗剂有效地重新激活了p53通路.
- 在过度表达MdmX和/或Mdm2.2的模型癌细胞中证明有效性.
- 建立了一个可行的小分子治疗候选者.
结论:
- 双抑制Mdm2和MdmX是癌症治疗的有效策略.
- 开发的双抗体是Mdm2/MdmX过度表达癌症的有希望的治疗候选者.
- 这项研究验证了一种针对瘤学中的p53-Mdm2/MdmX轴的新方法.
相关概念视频
Abnormal Proliferation
5.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.5K
DNA Damage can Stall the Cell Cycle
10.4K
In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
10.4K
DNA Damage Can Stall the Cell Cycle
3.4K
In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
3.4K
Negative Regulator Molecules
39.2K
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
39.2K
Inhibition of Cdk Activity
6.3K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.3K
The Intrinsic Apoptotic Pathway
9.4K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
9.4K

